ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT

The crizotinib-resistant ALK(F1174L) mutation arises de novo in neuroblastoma (NB) and is acquired in ALK translocation-driven cancers, lending impetus to the development of novel anaplastic lymphoma kinase (ALK) inhibitors with different modes of action. The diaminopyrimidine TAE684 and its derivat...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncogene
Hlavní autoři: Debruyne, D N, Bhatnagar, N, Sharma, B, Luther, W, Moore, N F, Cheung, N-K, Gray, N S, George, R E
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2016
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4885798/
https://ncbi.nlm.nih.gov/pubmed/26616860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2015.434
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky